2026-06-14T03:31:01Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/111212025-03-27T09:51:56Zcom_20.500.12105_19604com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19605col_20.500.12105_16938col_20.500.12105_16977

00925njm 22002777a 4500 dc González-Sánchez, Marta author Bartolome, Fernando author Antequera, Desireé author Puertas-Martín, Veronica author González, Pilar author Gómez-Grande, Adolfo author Llamas-Velasco, Sara author Herrero-San Martín, Alejandro author Pérez-Martínez, David author Villarejo-Galende, Alberto author Atienza, Mercedes author Palomar-Bonet, Miriam author Cantero, José Luis author Perry, George author Orive, Gorka author Ibáñez, Borja author Bueno, Hector author Fuster, Valentin author Carro, Eva author 2020-07 Background: Evidences of infectious pathogens in Alzheimer's disease (AD) brains may suggest a deteriorated innate immune system in AD pathophysiology. We previously demonstrated reduced salivary lactoferrin (Lf) levels, one of the major antimicrobial proteins, in AD patients. Methods: To assess the clinical utility of salivary Lf for AD diagnosis, we examine the relationship between salivary Lf and cerebral amyloid-β (Aβ) load using amyloid-Positron-Emission Tomography (PET) neuroimaging, in two different cross-sectional cohorts including patients with different neurodegenerative disorders. Findings: The diagnostic performance of salivary Lf in the cohort 1 had an area under the curve [AUC] of 0•95 (0•911-0•992) for the differentiation of the prodromal AD/AD group positive for amyloid-PET (PET+) versus healthy group, and 0•97 (0•924-1) versus the frontotemporal dementia (FTD) group. In the cohort 2, salivary Lf had also an excellent diagnostic performance in the health control group versus prodromal AD comparison: AUC 0•93 (0•876-0•989). Salivary Lf detected prodromal AD and AD dementia distinguishing them from FTD with over 87% sensitivity and 91% specificity. Interpretation: Salivary Lf seems to have a very good diagnostic performance to detect AD. Our findings support the possible utility of salivary Lf as a new non-invasive and cost-effective AD biomarker. EBioMedicine. 2020; 57:102834 10.1016/j.ebiom.2020.102834 2352-3964 EBioMedicine 32586758 http://hdl.handle.net/20.500.12105/11121 Decreased salivary lactoferrin levels are specific to Alzheimer's disease.